- Home
- RA vs OPT Comparison
RA vs OPT Comparison
Compare RA & OPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RA
- OPT
- Stock Information
- Founded
- RA 2016
- OPT 1984
- Country
- RA United States
- OPT Australia
- Employees
- RA N/A
- OPT N/A
- Industry
- RA Investment Managers
- OPT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- RA Finance
- OPT Health Care
- Exchange
- RA Nasdaq
- OPT Nasdaq
- Market Cap
- RA 739.7M
- OPT 767.9M
- IPO Year
- RA N/A
- OPT 2020
- Fundamental
- Price
- RA $13.14
- OPT $3.24
- Analyst Decision
- RA
- OPT Strong Buy
- Analyst Count
- RA 0
- OPT 1
- Target Price
- RA N/A
- OPT $12.00
- AVG Volume (30 Days)
- RA 280.8K
- OPT 39.0K
- Earning Date
- RA 01-01-0001
- OPT 08-30-2024
- Dividend Yield
- RA 14.73%
- OPT N/A
- EPS Growth
- RA N/A
- OPT N/A
- EPS
- RA N/A
- OPT N/A
- Revenue
- RA N/A
- OPT $261,859.00
- Revenue This Year
- RA N/A
- OPT N/A
- Revenue Next Year
- RA N/A
- OPT $46,864.64
- P/E Ratio
- RA N/A
- OPT N/A
- Revenue Growth
- RA N/A
- OPT N/A
- 52 Week Low
- RA $11.89
- OPT $1.79
- 52 Week High
- RA $17.32
- OPT $5.45
- Technical
- Relative Strength Index (RSI)
- RA 36.75
- OPT 27.29
- Support Level
- RA $13.29
- OPT $4.02
- Resistance Level
- RA $13.63
- OPT $4.18
- Average True Range (ATR)
- RA 0.14
- OPT 0.22
- MACD
- RA -0.03
- OPT -0.13
- Stochastic Oscillator
- RA 20.49
- OPT 6.85
About RA Brookfield Real Assets Income Fund Inc.
Brookfield Real Assets Income Fund Inc. is a diversified, closed-end management investment company. Its investment objective is to seek a high total return, through high current income and secondarily, through the growth of capital. The Fund seeks to achieve its investment objective by investing in the real asset class, which includes the following: Real Estate Securities; Infrastructure Securities; and Natural Resources Securities (collectively, Real Asset Companies and Issuers). The Firm manages separate accounts, registered funds, and opportunistic strategies for institutional and individual clients, including financial institutions, public and private pension plans, insurance companies, endowments and foundations, sovereign wealth funds, and high-net-worth investors.
About OPT Opthea Limited
Opthea Ltd operates in one industry being the medical technology and healthcare. It is focused on developing biological therapeutics for eye diseases. The company is developing a novel biologic therapy, OPT-302, for the treatment of eye diseases. Its products are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors C and D and R3 targets. Opthea's development activities are based on an intellectual property portfolio covering key targets Vascular Endothelial Growth Factors VEGF-C, VEGF-D and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. The company geographically operates Australia and United States.